Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study

PURPOSE: The Piedmont study is a prospectively designed retrospective evaluation of a new 48-gene antifolate response signature (AF-PRS) in patients with locally advanced/metastatic nonsquamous (NS) non–small cell lung cancer (NSCLC) treated with pemetrexed-containing platinum doublet chemotherapy (...

Descripción completa

Detalles Bibliográficos
Autores principales: Eisner, Joel R., Mayhew, Gregory M., Davison, James M., Beebe, Kirk D., Shibata, Yoichiro, Guo, Yuelong, Farhangfar, Carol, Farhangfar, Farhang, Uronis, Joshua M., Conroy, Jeffrey M., Milburn, Michael V., Hayes, David Neil, Mileham, Kathryn F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425722/
https://www.ncbi.nlm.nih.gov/pubmed/37233991
http://dx.doi.org/10.1158/1078-0432.CCR-22-2558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425722/
https://www.ncbi.nlm.nih.gov/pubmed/37233991
http://dx.doi.org/10.1158/1078-0432.CCR-22-2558

Ejemplares similares